G01N 2333/655
Somatostatins
G01N2333/655 (Somatostatins) appears on 12 US grants and 12 published applications in this corpus.
Search patents in G01N- Granted patents
- 12
- Published applications
- 12
- Assignees
- 12
- Inventors
- 42
- Latest grant
- 3 Feb 2015
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 1 |
| 2003 | 1 | 1 |
| 2004 | 1 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 1 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Peptide ligands of somatostatin receptors3 Feb 2015US 8,946,154 B2Bcn Peptides, S.A.
- Somatostatin receptor 2 antagonists8 Apr 2014US 8,691,761 B2
- Diagnosis and treatment of type 2 diabetes and other disorders1 Feb 2011US 7,879,859 B2Merck Sharp & Dohme Corp.
- Methods for identifying compounds for treating diabetes mellitus3 Jun 2008US 7,381,523 B2BioCrine AB
- Inhibition of amylin release10 Aug 2004US 6,774,109 B2Societe de Conseils de Recherches et d' Applications Scientifiques
- Somatostatin Receptor24 Aug 2023US 2023/0266316 A1
- Pancreatic endocrine cell indicating agent and utilization of same12 Jul 2012US 2012/0177571 A1Riken
- Peptide ligands of somatostatin receptors17 May 2012US 2012/0122781 A1Bcn Peptides, S.A.
- Diagnosis and treatment of type 2 diabetes and other disorders21 May 2009US 2009/0131451 A1Merck Sharp & Dohme Corp.
- Somatostatin receptor 2 antagonists4 Dec 2008US 2008/0299040 A1Salk Institute for Biological Studies Universitat Bern University Hospital Basel
Most cited
By later US patents
- Methods for identifying compounds for treating diabetes mellitus20US 7,381,523 B2BioCrine AB · 2008
- Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property14US 6,613,572 B2Fujisawa Pharmaceutical Co., Ltd. · 2003
- Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property13US 6,344,358 B12002
- Somatostatin receptor 2 antagonists11US 8,691,761 B22014
- Method for improving the accuracy of diagnosis of growth hormone deficiency8US 5,065,747 AUniversity of South Florida · 1991